Monday, October 18, 1993
After five years, Centocor Inc. presented encouraging findings from its study of the
Panorex monoclonal antibody in colorectal cancer, but indications are that both the
company and clinicians will want to see the results replicated in a larger study.
As of now, the company only plans to use the data for a January 1994 marketing filing in
CNTO and its marketing partner, Wellcome plc, haven't finalized their strategy for the
rest of Europe, CNTO President and CEO David Holveck told BioCentury. Holveck said
Wellcome believes there's an opportunity for a broader filing, based on the German study
and two shorter studies done in France and Sweden.
CNTO is being more conservative. "Our position is to initiate another two-year trial
in Europe and the United States," Holveck said. CNTO plans